ION 716
Alternative Names: ION-716Latest Information Update: 28 Feb 2024
At a glance
- Originator Ionis Pharmaceuticals
- Class Antisense oligonucleotides; Neuroprotectants
- Mechanism of Action Protein biosynthesis inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prion diseases